How does Helicobacter pylori infection relate to gastric adenocarcinoma and gastric MALT lymphoma, and what are the recommended eradication and surveillance strategies?

H. pylori and Malignancy: Gastric Adenocarcinoma and MALT Lymphoma

Relationship to Gastric Adenocarcinoma

H. pylori infection is the most consistent and important risk factor for gastric adenocarcinoma, accounting for 71-95% of all gastric cancers, and its elimination represents the most promising strategy to reduce gastric cancer incidence. 1

Carcinogenic Mechanisms

• Chronic active gastritis is the essential precursor: Gastric cancer is rare in the absence of chronic active gastritis, and the extent and severity of gastritis, atrophy, and intestinal metaplasia (IM) are positively associated with cancer risk 1
• Corpus-dominant gastritis confers highest risk: Patients with corpus-predominant H. pylori gastritis face substantially increased gastric cancer risk compared to antral-predominant patterns 1
• Hypochlorhydria enables carcinogenic bacterial overgrowth: Atrophic corpus gastritis causes hypochlorhydria, which allows non-H. pylori organisms to proliferate and produce metabolites with carcinogenic potential 1
• Oxidative stress and chronic inflammation: H. pylori induces decades-long inflammatory responses producing chronic oxidative stress that eventually leads to neoplastic transformation in a minority of infected individuals 2

Eradication and Cancer Prevention

H. pylori eradication reduces gastric cancer risk most effectively when performed before the development of preneoplastic conditions (atrophy and intestinal metaplasia). 1

• Strong evidence supports risk reduction: Meta-analyses demonstrate that H. pylori eradication leads to significant reduction in gastric cancer development 1
• Eradication abolishes inflammation and may reverse atrophy: Treatment stops the inflammatory response and slows or arrests progression of atrophy; in some cases, corpus atrophy may be reversible, though antral atrophy and IM are generally considered irreversible 1
• Timing is critical: The benefit is greatest when eradication occurs before extensive preneoplastic changes develop 1

Surveillance After Eradication

Individuals with confirmed gastric atrophy with or without IM require risk stratification, and those with severe atrophy and/or multifocal/incomplete IM should undergo endoscopic surveillance every 3 years, with shorter intervals if multiple risk factors exist (e.g., family history). 1

• Normal index endoscopy in high-risk patients: If screening endoscopy shows no atrophy, IM, or neoplasia, continue screening based on individual risk factors (particularly first-degree family history of gastric cancer) 1
• Failed eradication in high-risk patients: Despite eradication attempts, ongoing screening every 3-5 years should be considered in patients with family history or multiple risk factors 1
• Dysplasia requires expert confirmation: All dysplasia (indefinite, low-grade, or high-grade) must be confirmed by an experienced GI pathologist, and patients should be referred to centers with expertise in gastric neoplasia management 1

---

Relationship to Gastric MALT Lymphoma

H. pylori eradication with antibiotics is the sole initial therapy for localized H. pylori-positive gastric MALT lymphoma, inducing lymphoma regression and long-term disease control in most patients. 1

Diagnostic Requirements

• Multiple biopsies are mandatory: Obtain samples from all gastric regions, duodenum, gastroesophageal junction, and any abnormal-appearing sites 1
• H. pylori status must be determined: Use histochemistry, urea breath test, stool antigen test, or serology 1
• Test for t(11;18) translocation: FISH or PCR identifies patients unlikely to respond to antibiotics alone 1
• Complete staging includes: Endoscopic ultrasound for wall infiltration and lymph nodes, CT chest/abdomen/pelvis, bone marrow biopsy, complete blood counts, LDH, and β2-microglobulin 1

First-Line Treatment Algorithm

All gastric MALT lymphomas, regardless of stage, must receive H. pylori eradication therapy as initial treatment. 1

H. pylori-Positive Disease

• Standard eradication regimen: PPI plus clarithromycin-based triple therapy with either amoxicillin or metronidazole for 10-14 days 1
• Confirm eradication: Urea breath test or monoclonal stool antigen test at least 6 weeks after therapy and at least 2 weeks after PPI withdrawal 1
• Second-line if eradication fails: Alternative triple- or quadruple-therapy regimens with different antibiotics 1
• Wait 12 months before additional therapy: Even with persistent histological lymphoma, wait at least 12 months if clinical and endoscopic remission is achieved with H. pylori eradication 1
• Molecular persistence is common: Monoclonal B-cells frequently persist after histological regression; this does not mandate immediate treatment 1

H. pylori-Negative Disease

• Trial of antibiotics may be worthwhile: Occasional responses occur (possibly due to false-negative tests or other Helicobacter species) 1
• Reassess at 2-3 months: If no regression on repeat endoscopy, proceed to oncological treatment 1

Treatment for Refractory or Advanced Disease

For localized disease (stage I-II) that fails antibiotic therapy, involved-field radiotherapy (24-30 Gy over 3-4 weeks) is the preferred option. 1

• Radiotherapy delivers excellent disease control: Multiple institutions report excellent outcomes with moderate-dose radiation to stomach and perigastric nodes 1
• Systemic therapy for stage IV symptomatic disease: Rituximab plus chemotherapy (particularly rituximab-chlorambucil) is appropriate for disseminated symptomatic disease 1
• t(11;18)-positive patients: Likely unresponsive to alkylating agents as sole treatment; require combination therapy 1
• Surgery has no role: Surgery does not achieve superior results compared to conservative approaches and may impair quality of life 1

Surveillance Strategy

Strict endoscopic follow-up with multiple biopsies is mandatory: at 2-3 months post-treatment to confirm H. pylori eradication, then twice yearly for 2 years to monitor histological regression. 1

• Watch-and-wait for stable residual disease: Persistent but stable residual disease or transient histological relapses without H. pylori reinfection or distant dissemination can be safely observed 1
• Long-term surveillance is essential: Clinical examination, blood counts, and imaging every 12-18 months indefinitely 1
• Increased gastric adenocarcinoma risk: Patients with gastric MALT lymphoma have a sixfold higher risk of gastric adenocarcinoma than the general population, necessitating ongoing surveillance 1

---

Common Pitfalls and Caveats

• Do not skip H. pylori testing in stage IV MALT lymphoma: Even disseminated disease requires eradication therapy 1
• Do not treat persistent molecular disease immediately: Monoclonal B-cells after histological regression warrant observation, not immediate therapy 1, 3, 4
• Do not assume IM is reversible: Intestinal metaplasia is generally irreversible, though corpus atrophy may reverse in some cases 1
• Do not use serology for test of cure: Antibody levels remain elevated after eradication; use urea breath test or stool antigen test 5
• Do not test too early: Testing before 4 weeks post-treatment yields false-negative results 5
• Do not perform surgery for MALT lymphoma: Surgery offers no advantage and reduces quality of life 1